In this case study treating mCRPC with PARP inhibitors + novel hormonal agents, Dr. Andrew Armstrong walks us through a patient's journey, highlighting the importance of genetic testing to guide treatment, efficacy and safety of PARP inhibitor combos, and personalizing therapy based on HRR status. Watch the video to learn how to optimize treatment for your mCRPC patients! 📺 Thank you to COR2ED and GU CONNECT for sharing this great content. #ZEROProstateCancer #ProstateCancer #PrecisionMedicine
In this case study video, Dr Andrew Armstrong takes us through the treatment of a patient with metastatic castration-resistant prostate cancer. 👉 https://ow.ly/JW9850QeX14 How should we treat this patient using PARP inhibitors in combination with non-hormonal agents? Dr Armstrong guides us through this patient's germline and somatic genetic assessment and how the outcome impacts our choice of therapy. We are led through the latest trial data regarding the efficacy and side-effects of PARP inhibitors and how to use this information to guide our treatment choices. This program is endorsed by ZERO Prostate Cancer and NASPCC #MedEd #ProstateCancer #MedicalEducation #Oncology